Skip to main content
logo
Recce Pharmaceuticals Ltd (RECEF)
OTCMKTS · Delayed Price · Currency is USD
0.2200
-0.2800 (-56.00%)
At close: Jun 24, 2025

Recce Pharmaceuticals Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Other Revenue
7.515.034.373.081.64
Revenue
7.515.034.373.081.64
Revenue Growth (YoY)
49.33%15.19%41.50%88.41%45.97%
Cost of Revenue
10.457.227.416.335.7
Gross Profit
-2.94-2.19-3.05-3.25-4.07
Selling, General & Admin
8.367.095.753.542.29
Amortization of Goodwill & Intangibles
---0.14-
Other Operating Expenses
7.417.333.532.421.63
Operating Expenses
17.4714.819.836.49.44
Operating Income
-20.41-17-12.88-9.65-13.51
Interest Expense
-1.21-0.84-0.18-0.01-0.01
Interest & Investment Income
0.110.190.070.090.11
Currency Exchange Gain (Loss)
0.13-0---
Other Non Operating Income (Expenses)
-0.05-0.01-0.01-0-0.1
EBT Excluding Unusual Items
-21.43-17.66-12.99-9.57-13.51
Legal Settlements
---0.08-1.42-
Pretax Income
-21.43-17.66-13.08-10.99-13.51
Net Income
-21.43-17.66-13.08-10.99-13.51
Net Income to Common
-21.43-17.66-13.08-10.99-13.51
Shares Outstanding (Basic)
237177174174155
Shares Outstanding (Diluted)
237177174174155
Shares Change (YoY)
33.81%1.79%-0.09%12.05%22.17%
EPS (Basic)
-0.09-0.10-0.08-0.06-0.09
EPS (Diluted)
-0.09-0.10-0.08-0.06-0.09
Free Cash Flow
-20.47-13.15-12.73-9.05-7.93
Free Cash Flow Per Share
-0.09-0.07-0.07-0.05-0.05
Gross Margin
-39.12%-43.52%-69.83%-105.22%-248.40%
Operating Margin
-271.76%-338.04%-295.00%-312.74%-824.91%
Profit Margin
-285.37%-351.24%-299.58%-356.12%-825.30%
Free Cash Flow Margin
-272.59%-261.53%-291.53%-293.38%-484.42%
EBITDA
-20.33-16.93-12.83-9.6-13.39
EBITDA Margin
-270.81%--293.92%--
D&A For EBITDA
0.070.070.050.050.12
EBIT
-20.41-17-12.88-9.65-13.51
EBIT Margin
-271.76%--295.00%--
Advertising Expenses
1.241.241.120.990.7
Source: S&P Global Market Intelligence. Standard template. Financial Sources.